<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570542</url>
  </required_header>
  <id_info>
    <org_study_id>15-193</org_study_id>
    <nct_id>NCT02570542</nct_id>
  </id_info>
  <brief_title>Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Seidman Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the impact of stem cell dose on outcome after
      autologous transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the
      treating attending physician with the plerixafor for the achievement of &gt;6 x10^6 CD34+
      cells/kg. The patients that fail to mobilize &gt;6 x10^6 CD34+ cells/kg will not be randomized
      and will subsequently be followed for disease progression and overall survival.. Patients
      with &gt;6 x10^6 CD34+ cells/kg cryopreserved on study will be admitted to the hospital for
      planned ASCT. Patients will be randomly infused with either 3-4 x 10^6 CD34+ stem cells/kg or
      6-8 x10^6 CD34+ stem cells/kg on d0 per study randomization. The cell dose ranges within the
      two groups allows variability within aliquots of cells at the time of cryopreservation.
      Patients will receive standard supportive measures (including: growth factor support
      post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and
      treatment for neutropenic fever) as per institutional guideline practices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>at +/- 2 weeks</time_frame>
    <description>equals date of progression/death - date of Autologous Stem Cell Transplantation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Relapsed Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Refractory Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>3-4 x 10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-8 x10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>leukapheresis</intervention_name>
    <arm_group_label>3-4 x 10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_label>6-8 x10^6 CD34+ stem cells/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.</description>
    <arm_group_label>3-4 x 10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_label>6-8 x10^6 CD34+ stem cells/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine, etoposide, cytarabine, melphalan</intervention_name>
    <description>Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.</description>
    <arm_group_label>3-4 x 10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_label>6-8 x10^6 CD34+ stem cells/kg</arm_group_label>
    <other_name>BEAM chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <arm_group_label>3-4 x 10^6 CD34+ stem cells/kg</arm_group_label>
    <arm_group_label>6-8 x10^6 CD34+ stem cells/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Diagnosed with relapsed or refractory de novo DLBCL or follicular lymphoma transformed
             to DLBCL to one previous line of anthracycline-containing chemotherapy

          -  KPS ≥ 70

          -  Complete or partial response by IWG Working Group or ICML Criteria to maximum of one
             salvage line of chemotherapy without pre-HDT/ASCT salvage radiotherapy.

          -  Eligible for high-dose therapy and autologous stem-cell rescue

               -  Serum creatinine ≤ 1.5 mg/dL, or if creatinine &gt;1.5 mg/dL, calculated creatinine
                  clearance of ≥50 mL/min by 24 hour creatinine clearance or CKD-EPI.

               -  Last cycle of most recent salvage therapy within 8 weeks of enrollment

          -  Total bilirubin &lt; 2.0 mg/dL

             o If Gilbert‟s disease is suspected and total bilirubin &gt; 2.0 mg/dL, direct bilirubin
             must be &lt; 2.0 mg/dL

          -  Females of childbearing potential and males must agree to use an acceptable form of
             contraception per institutional practices.

        Exclusion Criteria:

          -  Disease progression by IWG Working Group or ICML Criteria since last therapy

          -  Prior autologous or allogeneic stem cell transplantation

          -  HIV infection

          -  Comorbid condition(s) which, in the opinion of the attending physician and/or MSKCC
             Principal Investigator, will preclude stem cell mobilization and/or high-dose therapy
             with autologous stem cell rescue

          -  Treatment plan that includes post-transplant maintenance therapy

          -  Salvage therapy that includes involved field radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sauter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Sauter, MD</last_name>
    <phone>212-639-3460</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Giralt, MD</last_name>
    <phone>212-639-6009</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthee-lu Bayer, MD</last_name>
      <phone>516-734-8973</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
    <contact_backup>
      <last_name>Sergio Giralt, MD</last_name>
      <phone>212-639-6009</phone>
    </contact_backup>
    <investigator>
      <last_name>Craig Sauter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Mapara, MD</last_name>
      <phone>212-305-5098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Becker, MD</last_name>
      <phone>585-275-5823</phone>
    </contact>
    <investigator>
      <last_name>Michael Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Caimi, MD</last_name>
      <phone>216-844-3951</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bachier, MD</last_name>
      <phone>615-342-7440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shaughnessy, MD</last_name>
      <phone>210-575-3817</phone>
    </contact>
    <investigator>
      <last_name>Paul Shaughnessy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Shah, MD</last_name>
      <phone>414-955-8296</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD34+ Cell Dose</keyword>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>15-193</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

